• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jupiter Neurosciences, Inc. - Common Stock (NQ:JUNS)

    1.079 -0.031 (-2.78%)
    Streaming Delayed Price Updated: 3:54 PM EST, Dec 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 118,529
    Open 1.110
    Bid (Size) 1.020 (300)
    Ask (Size) 1.110 (900)
    Prev. Close 1.110
    Today's Range 1.050 - 1.160
    52wk Range 0.5100 - 11.43
    Shares Outstanding 34,426,355
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    From FDA Clearance To The Launch Of A Consumer Line, Jupiter Neurosciences Hit Milestones In 2025; More On The Horizon
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    News headline image
    From FDA Clearance To The Launch Of A Consumer Line, Jupiter Neurosciences Hit Milestones In 2025; More On The Horizon
    Via TheNewswire.com

    Performance

    YTD
    -89.7%
    -89.7%
    1 Month
    -10.1%
    -10.1%
    3 Month
    -40.1%
    -40.1%
    6 Month
    +5.8%
    +5.8%
    1 Year
    -89.5%
    -89.5%

    More News

    Read More
    News headline image
    Jupiter Neurosciences Brings Its Brain Health Expertise To The Masses With Nugevia - And A Range Of Celebs From Athletes To Scientists Are Customers
    Via NewMediaWire
    News headline image
    Jupiter Neurosciences Brings Its Brain Health Expertise To The Masses With Nugevia - And A Range Of Celebs From Athletes To Scientists Are Customers
    Via TheNewswire.com
    News headline image
    Jupiter Neurosciences CEO And President Talk About The Power of JOTROL And The Launch of Its Longevity Consumer Line With Benzinga
    Via TheNewswire.com
    News headline image
    Jupiter Neurosciences CEO And President Talk About The Power of JOTROL And The Launch of Its Longevity Consumer Line With Benzinga
    Via NewMediaWire
    News headline image
    Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) Brand
    Via NewMediaWire
    News headline image
    Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) Brand
    Via TheNewswire.com
    News headline image
    There are notable gap-ups and gap-downs in today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    From Fighting Inflammation To Regenerating Cells: How Jupiter Neurosciences Is Putting The Pep Back In Our Step As We Age
    Via NewMediaWire
    News headline image
    From Fighting Inflammation To Regenerating Cells: How Jupiter Neurosciences Is Putting The Pep Back In Our Step As We Age
    Via TheNewswire.com
    News headline image
    Which stocks are moving after the closing bell on Friday? ↗
    Via Chartmill
    News headline image
    Top movers in Thursday's after hours session ↗
    Via Chartmill
    News headline image
    Top stock movements in today's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    News headline image
    How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success
    Via NewMediaWire
    News headline image
    How Jupiter Neuroscience's Two-Prong Approach Could Crack The Code On Biotech Success
    Via TheNewswire.com
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's After-Market Session ↗
    Via Benzinga
    News headline image
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
    Via Benzinga
    News headline image
    Unusual volume stocks are being observed in Thursday's session. ↗
    Via Chartmill

    Frequently Asked Questions

    Is Jupiter Neurosciences, Inc. - Common Stock publicly traded?
    Yes, Jupiter Neurosciences, Inc. - Common Stock is publicly traded.
    What exchange does Jupiter Neurosciences, Inc. - Common Stock trade on?
    Jupiter Neurosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Jupiter Neurosciences, Inc. - Common Stock?
    The ticker symbol for Jupiter Neurosciences, Inc. - Common Stock is JUNS on the Nasdaq Stock Market
    What is the current price of Jupiter Neurosciences, Inc. - Common Stock?
    The current price of Jupiter Neurosciences, Inc. - Common Stock is 1.079
    When was Jupiter Neurosciences, Inc. - Common Stock last traded?
    The last trade of Jupiter Neurosciences, Inc. - Common Stock was at 12/30/25 03:54 PM ET
    What is the market capitalization of Jupiter Neurosciences, Inc. - Common Stock?
    The market capitalization of Jupiter Neurosciences, Inc. - Common Stock is 37.15M
    How many shares of Jupiter Neurosciences, Inc. - Common Stock are outstanding?
    Jupiter Neurosciences, Inc. - Common Stock has 37M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.